Fig. 6

EZH2 inhibition improves in vivo tumor response to cisplatin in HB PDX model. HB66 PDX model was pretreated with 150 mg/kg EPZ-6438 5 times per week. 5 mg/kg cisplatin was then started and EPZ-6438 continued to study termination. a. MRI images show tumor volume at initiation of treatment and at 2 weeks of treatment. b. Reduction of H3K27me³ is shown following EPZ-6438 and cisplatin treatments alone, but enhanced, synergistic reduction is seen after combination treatment with EPZ-6438.  c. When comparing tumor volume, cisplatin alone showed modest reduction in tumor growth, while EPZ-6438 and cisplatin plus EPZ-6438 showed even greater reduction in overall tumor growth, supportive of in vitro studies. (one PDX model, with biological duplicate or triplicate per condition).